Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: SLV026
MIFTS: 57

Salivary Gland Carcinoma

Categories: Cancer diseases, Endocrine diseases, Gastrointestinal diseases, Oral diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Salivary Gland Carcinoma

About this section

MalaCards integrated aliases for Salivary Gland Carcinoma:

Name: Salivary Gland Carcinoma 12 15
Salivary Gland Cancer 12 36 54 42 15
Malignant Neoplasm of Salivary Gland 12

Classifications:

MalaCards categories:
Global: Cancer diseases Rare diseases
Anatomical: Oral diseases Gastrointestinal diseases Endocrine diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

Disease Ontology 12 DOID:0050904 DOID:8850
KEGG 36 H01508
ICD9CM 34 142.8
ICD10 32 C08
UMLS 71 C0153362
Sources

Summaries for Salivary Gland Carcinoma

About this section
KEGG : 36 Salivary gland carcinomas are rare tumours representing about 0.5% of all malignancies and less than 5 % of all head and neck cancers. These are a heterogeneous group of tumors that include 24 histologically distinct tumor types. Mucoepidermoid carcinoma (MEC) is the most common malignant salivary gland tumor in adults and children. The most common genetic alteration in MECs is a unique translocation t(11;19)(q21;p13) producing the MECT1-MAML2 fusion protein. This fusion transcript can activate transcription of targets in the Notch pathway. Epidermal growth factor receptor (EGFR) and human epidermal growth factor receptor 2 (HER2) overexpression is present in a minority of MECs and is associated with higher rate of metastasis and worse overall survival. Recent studies have evaluated the epidermal growth factor receptor family including EGFR and HER2 as potential therapeutic targets.

MalaCards based summary : Salivary Gland Carcinoma, also known as salivary gland cancer, is related to mucoepidermoid carcinoma and pleomorphic adenoma. An important gene associated with Salivary Gland Carcinoma is MET (MET Proto-Oncogene, Receptor Tyrosine Kinase), and among its related pathways/superpathways are Notch signaling pathway and ERK Signaling. The drugs Iodine and Cisplatin have been mentioned in the context of this disorder. Affiliated tissues include salivary gland, testes and lymph node, and related phenotypes are Decreased viability and Decreased viability

Disease Ontology : 12 An oral cavity cancer that is located in the salivary gland.

MedlinePlus : 42 Your salivary glands make saliva - sometimes called spit - and empty it into your mouth through openings called ducts. Saliva makes your food moist, which helps you chew and swallow. It helps you digest your food. It also cleans your mouth and contains antibodies that can kill germs. Salivary gland cancer is a type of head and neck cancer. It is rare. It may not cause any symptoms, or you could notice A lump in your ear, cheek, jaw, lip, or inside the mouth Fluid draining from your ear Trouble swallowing or opening the mouth widely Numbness, weakness, or pain in your face Doctors diagnose salivary gland cancer using a physical exam, imaging tests, and a biopsy. Treatment can include surgery, radiation therapy, and/or chemotherapy. NIH: National Cancer Institute

Sources

Related Diseases for Salivary Gland Carcinoma

About this section

Diseases in the Salivary Gland Carcinoma family:

Salivary Gland Cancer, Adult

Diseases related to Salivary Gland Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 242)
# Related Disease Score Top Affiliating Genes
1 mucoepidermoid carcinoma 33.3 SERPINA3 MAML2 EGFR CRTC1 CDKN2A
2 pleomorphic adenoma 31.6 MDM2 MAML2 CRTC1 CDKN2A
3 adenocarcinoma 31.5 MET MDM2 KIT HGF EGFR CDKN2A
4 adenoid cystic carcinoma 31.5 SOX2 SERPINA3 MDM2 KIT EGFR CYLD
5 pleomorphic adenoma carcinoma 31.1 MAML2 CRTC1
6 mucinous adenocarcinoma 30.8 KIT EGFR CDKN2A
7 exanthem 30.7 KIT H2AC18 EGFR
8 small cell carcinoma 30.7 KIT EGFR CDKN2A
9 basal cell carcinoma 30.7 SOX2 KIT EGFR CYLD CDKN2A
10 lymphoma 30.4 MET MDM2 KIT EGFR CDKN2A BRCA1
11 lung cancer susceptibility 3 30.0 SOX2 SERPINA3 MET MDM2 KIT HGF
12 salivary gland disease 29.4 TST SERPINA3 NR4A1 MAML2 KIT ISL1
13 salivary gland cancer, adult 12.7
14 sublingual gland cancer 11.3
15 chronic erosive gastritis 10.7 MET HGF
16 mediastinum liposarcoma 10.7 MDM2 CDKN2A
17 malignant peritoneal mesothelioma 10.7 EGFR CDKN2A
18 esophagus verrucous carcinoma 10.7 MDM2 EGFR CDKN2A
19 verrucous carcinoma 10.7 MDM2 EGFR CDKN2A
20 cervical adenoid cystic carcinoma 10.7 KIT CDKN2A
21 hereditary melanoma 10.7 MDM2 CDKN2A
22 doxorubicin induced cardiomyopathy 10.7 MET HGF EGFR
23 vulvar disease 10.7 KIT EGFR CDKN2A
24 gastric liposarcoma 10.7 MDM2 KIT
25 retroperitoneum carcinoma 10.7 MDM2 KIT CDKN2A
26 carcinosarcoma 10.7 KIT EGFR CDKN2A
27 hypopharynx cancer 10.7 MET EGFR CDKN2A
28 gliomatosis cerebri 10.7 MDM2 EGFR CDKN2A
29 acral lentiginous melanoma 10.7 MET KIT CDKN2A
30 basaloid squamous cell carcinoma 10.7 SOX2 EGFR CDKN2A
31 laryngeal small cell carcinoma 10.7 KIT CDKN2A
32 inflammatory liposarcoma 10.7 MDM2 CDKN2A
33 keratinizing squamous cell carcinoma 10.6 MAML2 EGFR CDKN2A
34 peritoneal mesothelioma 10.6 MET EGFR CDKN2A
35 anus basaloid carcinoma 10.6 KIT CYLD
36 breast malignant phyllodes tumor 10.6 SERPINA3 KIT EGFR
37 anus cancer 10.6 H2AC18 EGFR CDKN2A
38 embryonal sarcoma 10.6 SERPINA3 MDM2 KIT
39 tenosynovial giant cell tumor 10.6 SERPINA3 KIT CDKN2A
40 malignant spindle cell melanoma 10.6 SERPINA3 KIT CDKN2A
41 undifferentiated embryonal sarcoma of the liver 10.6 SERPINA3 MDM2
42 fibrosarcoma of bone 10.6 SERPINA3 KIT CDKN2A
43 heart cancer 10.6 SERPINA3 MDM2 KIT
44 lacrimal gland mucoepidermoid carcinoma 10.6 MAML2 CRTC1
45 schneiderian carcinoma 10.6 MAML2 CRTC1
46 malignant spiradenoma 10.6 MDM2 CYLD CDKN2A
47 deafness, autosomal recessive 97 10.6 SERPINA3 MET HGF
48 lung benign neoplasm 10.6 MET EGFR CDKN2A
49 cutaneous solitary mastocytoma 10.6 SERPINA3 KIT
50 lung adenoma 10.6 H2AC18 EGFR CDKN2A

Graphical network of the top 20 diseases related to Salivary Gland Carcinoma:



Diseases related to Salivary Gland Carcinoma
Sources

Symptoms & Phenotypes for Salivary Gland Carcinoma

About this section

GenomeRNAi Phenotypes related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-1 9.83 EGFR
2 Decreased viability GR00055-A-2 9.83 EGFR
3 Decreased viability GR00221-A-1 9.83 CDKN2A EGFR HGF SOX2 CYLD KIT
4 Decreased viability GR00221-A-2 9.83 HGF CYLD
5 Decreased viability GR00221-A-3 9.83 CDKN2A
6 Decreased viability GR00221-A-4 9.83 BRD3 CDKN2A EGFR HGF SOX2
7 Decreased viability GR00249-S 9.83 CYLD
8 Decreased viability GR00301-A 9.83 CYLD KIT
9 Decreased viability GR00402-S-2 9.83 CYLD

MGI Mouse Phenotypes related to Salivary Gland Carcinoma:

45 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.42 ACTN4 BRCA1 CDKN2A EGFR HGF ISL1
2 endocrine/exocrine gland MP:0005379 10.41 ACTN4 BRCA1 CDKN2A CRTC1 CYLD EGFR
3 cellular MP:0005384 10.38 ACTN4 BRCA1 CDKN2A CYLD EGFR HGF
4 growth/size/body region MP:0005378 10.37 ACTN4 BRCA1 CDKN2A CRTC1 CYLD EGFR
5 homeostasis/metabolism MP:0005376 10.35 ACTN4 BRCA1 CDKN2A CRTC1 CYLD EGFR
6 immune system MP:0005387 10.34 ACTN4 BRCA1 CDKN2A CRTC1 CYLD EGFR
7 hematopoietic system MP:0005397 10.33 ACTN4 BRCA1 CDKN2A CRTC1 CYLD EGFR
8 embryo MP:0005380 10.32 ACTN4 BRCA1 CDKN2A EGFR HGF ISL1
9 digestive/alimentary MP:0005381 10.28 ACTN4 BRCA1 CDKN2A CYLD EGFR ISL1
10 mortality/aging MP:0010768 10.27 ACTN4 BRCA1 CDKN2A CYLD EGFR HGF
11 integument MP:0010771 10.21 BRCA1 CDKN2A CYLD EGFR ISL1 KIT
12 craniofacial MP:0005382 10.14 ACTN4 EGFR ISL1 KIT MDM2 MET
13 neoplasm MP:0002006 10.14 ACTN4 BRCA1 CDKN2A CYLD EGFR ISL1
14 muscle MP:0005369 10.13 ACTN4 BRCA1 CDKN2A EGFR ISL1 KIT
15 liver/biliary system MP:0005370 10.08 ACTN4 CDKN2A EGFR HGF KIT MDM2
16 limbs/digits/tail MP:0005371 10.04 BRCA1 CYLD EGFR ISL1 KIT MDM2
17 normal MP:0002873 10.02 BRCA1 CYLD EGFR ISL1 KIT MDM2
18 no phenotypic analysis MP:0003012 9.97 CDKN2A EGFR HGF ISL1 KIT MDM2
19 renal/urinary system MP:0005367 9.76 ACTN4 BRCA1 EGFR ISL1 KIT MDM2
20 pigmentation MP:0001186 9.73 BRCA1 CDKN2A EGFR KIT MDM2 SOX2
21 reproductive system MP:0005389 9.65 BRCA1 CDKN2A CRTC1 EGFR ISL1 KIT
22 respiratory system MP:0005388 9.23 ACTN4 BRCA1 CDKN2A CYLD EGFR KIT
Sources

Drugs & Therapeutics for Salivary Gland Carcinoma

About this section

Drugs for Salivary Gland Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 159)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Iodine Approved, Investigational Phase 3 7553-56-2 807
2
Cisplatin Approved Phase 3 15663-27-1 2767 441203 84093
3
Cevimeline Approved Phase 3 107233-08-9 83898 25137844
4
leucovorin Approved Phase 3 58-05-9 6006 143
5
Methotrexate Approved Phase 3 59-05-2, 1959-05-2 126941
6
Promethazine Approved, Investigational Phase 3 60-87-7 4927
7
Doxepin Approved, Investigational Phase 3 1668-19-5 667477 667468
8
Histamine Approved, Investigational Phase 3 51-45-6 774
9
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
10
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
11
Pilocarpine Approved, Investigational Phase 2, Phase 3 54-71-7, 92-13-7 5910
12
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
13 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
14 cadexomer iodine Phase 3
15 Neurotransmitter Agents Phase 3
16 Muscarinic Agonists Phase 3
17 Cholinergic Agents Phase 3
18 Cola Phase 3
19 Liver Extracts Phase 3
20 Analgesics Phase 3
21 Vitamin B Complex Phase 3
22 Folic Acid Antagonists Phase 3
23 Folate Phase 3
24 Dermatologic Agents Phase 3
25 Vitamin B9 Phase 3
26 Antidepressive Agents Phase 3
27 Hypnotics and Sedatives Phase 3
28 Histamine Antagonists Phase 3
29 Psychotropic Drugs Phase 3
30
Histamine Phosphate Phase 3 51-74-1 65513
31 Antidepressive Agents, Tricyclic Phase 3
32 Anesthetics Phase 3
33 Narcotics Phase 3
34 Analgesics, Opioid Phase 3
35 Anesthetics, General Phase 3
36 Anesthetics, Intravenous Phase 3
37
Nintedanib Approved Phase 2 656247-17-5 56843413
38
Parathyroid hormone Approved, Investigational Phase 2 9002-64-6
39
Temoporfin Approved, Investigational Phase 2 122341-38-2
40
Epinephrine Approved, Vet_approved Phase 2 51-43-4 5816
41
Racepinephrine Approved Phase 2 329-65-7 838
42
Indinavir Approved Phase 2 150378-17-9 5362440
43
Ritonavir Approved, Investigational Phase 2 155213-67-5 392622
44
Sorafenib Approved, Investigational Phase 2 284461-73-0 216239 406563
45
Gemcitabine Approved Phase 2 95058-81-4 60750
46
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
47
Gefitinib Approved, Investigational Phase 2 184475-35-2 123631
48
Sargramostim Approved, Investigational Phase 2 83869-56-1, 123774-72-1
49
Aldesleukin Approved Phase 2 85898-30-2, 110942-02-4
50
Cetuximab Approved Phase 2 205923-56-4 56842117 2333

Interventional clinical trials:

(show top 50) (show all 138)
# Name Status NCT ID Phase Drugs
1 A Randomized Control Trial (RCT) of Using Iodine-125 Brachytherapy Versus Intensity-modulated Radiation Therapy (IMRT) to Treat Inoperable Salivary Gland Cancer Unknown status NCT02048254 Phase 3
2 A Multinational, Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase III Clinical Trial to Determine the Efficacy and Safety of IB-367 Rinse in Reducing the Severity of Oral Mucositis in Patients Receiving Radiotherapy for Head and Neck Malignancy Unknown status NCT00022373 Phase 3 iseganan HCl oral solution
3 A Multicenter Randomized Study of Cochlear Sparing Intensity Modulated Radiotherapy Versus Conventional Radiotherapy in Patients With Parotid Tumors Unknown status NCT01216800 Phase 3
4 A Randomized Controlled Trial Of CHARTWEL (a Continuous Hyperfractionated Accelerated Radiotherapy Schedule) Versus Conventional Radiotherapy In Post-Operative Head And Neck Cancer Patients Completed NCT00021125 Phase 3
5 A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy and Safety of Cevimeline in the Treatment of Xerostomia Secondary to Radiation Therapy for Cancer in the Head and Neck Region Completed NCT00017511 Phase 3 cevimeline hydrochloride
6 Phase III Randomized Trial of Methotrexate vs. Paclitaxel in Cisplatin-Ineligible Patients With Advanced Squamous Cell Carcinoma of the Head and Neck Completed NCT00003592 Phase 3 methotrexate;paclitaxel
7 Acupuncture for Pain and Dysfunction Following Neck Dissection: A Randomized, Controlled, Phase III Trial Completed NCT00090337 Phase 3
8 A Randomized Double-Blind Study of Doxepin Rinse Versus Placebo in the Treatment of Acute Oral Mucositis Pain in Patients Receiving Radiotherapy With or Without Chemotherapy Completed NCT01156142 Phase 3 doxepin hydrochloride
9 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
10 A Phase II/III Study Comparing Acupuncture-like Transcutaneous Electrical Nerve Stimulation (ALTENS) Versus Pilocarpine in Treating Early Radiation-Induced Xerostomia Completed NCT00656513 Phase 2, Phase 3 Pilocarpine
11 Phase III Randomized Study of Hypericum Perforatum (St. John's Wort) Combined With Docetaxel in Patients With Unresectable Solid Tumors Withdrawn NCT00041171 Phase 3 Hypericum perforatum;docetaxel
12 Phase II Trial of BIBF1120 (Nintedanib) in Patients With Recurrent or Metastatic Salivary Gland Cancer of the Head and Neck : a Multicentre Phase II Study Unknown status NCT02558387 Phase 2 BIBF1120
13 A Pilot Study of Amifostine and Concomitant Cisplatin, Paclitaxel and Radiotherapy in Previously Irradiated, Recurrent Head and Neck Cancer Unknown status NCT00003251 Phase 1, Phase 2 amifostine trihydrate;cisplatin;paclitaxel
14 A Phase I/II Study Using Cisplatin and Gemcitabine (Gemzar) for Advanced Head and Neck Cancer (Squamous Cell Carcinoma) Unknown status NCT00003182 Phase 1, Phase 2 cisplatin;gemcitabine hydrochloride
15 A Multicenter, Multi-National, Open-Label, Single Group, Single and Multiple Dose Study of Foscan-Mediated Photodynamic Therapy (PDT) for the Palliative Treatment of Recurrent, Refractory or Second Primary Squamous Cell Carcinomas of the Head and Neck in Patients Considered to be Incurable With Surgery or Radiotherapy Unknown status NCT00003856 Phase 2 temoporfin
16 A Phase II Activity And Safety Study Of IntraDose (Cisplatin/Epinephrine Injectable Gel) When Given In Combination With Systematic Chemotherapy Paclitaxel And Carboplatin In The Treatment Of Patients With Squamous Cell Carcinoma Of The Head And Neck At First Relapse Unknown status NCT00022217 Phase 2 carboplatin;cisplatin-e therapeutic implant;paclitaxel
17 Radiation Therapy in Combination With Indinavir / Ritonavir (Crixivan / Norvir) for the Treatment of Brain Metastases: a Randomized Phase II Study Unknown status NCT00637637 Phase 2 indinavir sulfate;ritonavir
18 Sorafenib in Recurrent and/or Metastatic Salivary Gland Carcinomas: Phase II Study Completed NCT01703455 Phase 2 Sorafenib
19 Gemcitabine for Advanced Salivary Cancer: A Phase II Study Completed NCT00003744 Phase 2 gemcitabine
20 PHASE II TRIAL OF TAXOL IN ADVANCED OR METASTATIC SALIVARY GLAND MALIGNANCIES Completed NCT00002632 Phase 2 paclitaxel
21 Phase II Trial of Eribulin for Locally Advanced Refractory or Metastatic Salivary Gland Cancers Completed NCT01613768 Phase 2 eribulin mesylate
22 Herceptin In Patients With Advanced or Metastatic Salivary Gland Carcinomas Completed NCT00004163 Phase 2 Trastuzumab
23 A Phase 2 Study Of Imatinib Mesylate In Adenoid Cystic, Lymphoepithelioma-Like And Myoepithelial Salivary Gland Carcinomas Completed NCT00045669 Phase 2 imatinib mesylate
24 A Phase II Study of Cisplatin and Gemcitabine in Patients With Locally Advanced/Recurrent or Metastatic Malignant Salivary Gland Tumors Completed NCT00079079 Phase 2 carboplatin;cisplatin;gemcitabine hydrochloride
25 Phase II Study of Pazopanib in Patients With Progressive Recurrent and/or Metastatic Salivary Gland Carcinoma Completed NCT02393820 Phase 2 pazopanib
26 Phase II Study On Gemcitabine In Recurrent Or Metastatic Adenoid Cystic Carcinoma Of The Head And Neck Completed NCT00017498 Phase 2 gemcitabine hydrochloride
27 Phase 2 Study Assessing the Impact of Parenteral Administration of the Immunomodulater Oral IMPACT® for Postoperative Radiochemotherapy in Patients With Carcinoma of the Head and Neck Completed NCT00559156 Phase 2 cisplatin
28 Pilot Study of the Relationship Between EF5 Uptake and Concentration of Oxygen-Related Metabolites in Head and Neck Cancer Completed NCT00049140 Phase 2 EF5
29 Phase II Study of ZD1839 (Iressa®), Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor in Patients With Advanced, Recurrent or Metastatic Salivary Gland Cancer (IRUSIRES0198) Completed NCT00509002 Phase 2 Gefitinib
30 Phase II Trial Of Weekly Irinotecan And Docetaxel In Recurrent Or Metastatic Head And Neck Carcinoma Completed NCT00040807 Phase 2 docetaxel;irinotecan hydrochloride
31 A Phase II Trial of Daily Bolus Flavopiridol for Five Consecutive Days in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN) Completed NCT00020189 Phase 2 acetylsalicylic acid;alvocidib;clopidogrel bisulfate
32 Phase II Evaluation of Weekly Cisplatin and Gemcitabine in the Treatment of Advanced (Recurrent or Metastatic) Carcinoma of the Head and Neck Completed NCT00003264 Phase 2 cisplatin;gemcitabine hydrochloride
33 Phase I/II Trial of the Epothilone B Analogue BMS 247550 (NSC 710428)/Cisplatin in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck Completed NCT00057850 Phase 1, Phase 2 cisplatin;ixabepilone
34 Re-irradiation and Stereotactic Cetuximab in Patients With Recurrent Carcinoma of the Head and Neck Completed NCT00738868 Phase 2
35 A Phase 2 Study of GW572016 in Recurrent and/or Metastatic Adenoid Cystic Carcinoma, and Other EGFR-and/or erbB2-expressing Malignant Tumors of the Salivary Glands Completed NCT00095563 Phase 2 lapatinib ditosylate
36 A Phase 2 Trial of GW572016 in Patients With Metastatic and Recurrent Squamous Cell Carcinomas of the Head and Neck Completed NCT00114283 Phase 2 lapatinib ditosylate
37 Treatment of Relapsed or Metastatic Head and Neck Carcinomas With Oxaliplatin and Capecitabine Completed NCT00448552 Phase 2 capecitabine;oxaliplatin
38 Pilot Randomized Trial Of Adjuvant Celecoxib In Patients With Early Stage Head And Neck And Non-Small Cell Lung Cancers Completed NCT00058006 Phase 2 celecoxib
39 Phase II Trial of Irinotecan Plus Cisplatin in Patients With Recurrent or Metastatic Squamous Carcinoma of the Head and Neck Completed NCT00639769 Phase 2 cisplatin;irinotecan hydrochloride
40 Celecoxib In Biomarker Modulation Of Oral Precancerous Lesions: A Pilot Study Completed NCT00052611 Phase 2 Celecoxib
41 A Phase II Study of Gemcitabine in Combination With Doxorubicin for Patients With Head and Neck Cancer Completed NCT00509665 Phase 2 doxorubicin hydrochloride;gemcitabine hydrochloride
42 A Study of Population Pharmacokinetics of Docetaxel (Taxotere) in Caucasian and African-American Cancer Patients Completed NCT00003565 Phase 2 docetaxel
43 Phase II Study of Single-Agent Cetuximab for Treatment of High-Risk Pre-malignant Upper Aerodigestive Lesions Completed NCT00524017 Phase 2
44 A Phase I and Phase II Study of OSI-774 in Combination With Docetaxel in Squamous Cell Carcinoma of the Head and Neck Completed NCT00055770 Phase 1, Phase 2 erlotinib hydrochloride;docetaxel
45 A Phase I/II Trial of Epirubicin, Carboplatin & Capecitabine in Adult Cancer Patients Completed NCT00021047 Phase 1, Phase 2 capecitabine;carboplatin;epirubicin hydrochloride
46 Vaccine Therapy With Tumor Specific Mutated Ras Peptides and IL-2 or GM-CSF for Adult Patients With Solid Tumors Completed NCT00019331 Phase 2 DetoxPC
47 Phase II Evaluation Of Paclitaxel And Cisplatin In Combination With Split Course Hyperfractionated Radiation Therapy And Granulocyte-Colony Stimulating Factor In Previously Irradiated Patients With Locally Recurrent Carcinoma Of The Head And Neck, And Lung Completed NCT00021333 Phase 2 cisplatin;paclitaxel
48 Dual Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Salivary Gland Cancers Recruiting NCT03749460 Phase 1, Phase 2
49 A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects With Advanced Solid Tumors (KEYNOTE 158) Recruiting NCT02628067 Phase 2
50 A Multicenter Phase I/II Trial of A Novel MDM2 Inhibitor(APG-115) With or Without Platinum Chemotherapy in P53 Wild-Type Salivary Gland Carcinoma Recruiting NCT03781986 Phase 1, Phase 2 APG115 mono-therapy;APG115 + Carboplatin

Search NIH Clinical Center for Salivary Gland Carcinoma

Sources

Genetic Tests for Salivary Gland Carcinoma

About this section
Sources

Anatomical Context for Salivary Gland Carcinoma

About this section

The Foundational Model of Anatomy Ontology organs/tissues related to Salivary Gland Carcinoma:

19
Salivary Gland

MalaCards organs/tissues related to Salivary Gland Carcinoma:

40
Salivary Gland, Testes, Lymph Node, Lung, Breast, Thyroid, Brain
Sources

Publications for Salivary Gland Carcinoma

About this section

Articles related to Salivary Gland Carcinoma:

(show top 50) (show all 660)
# Title Authors PMID Year
1
Transcriptome analyses identify hub genes and potential mechanisms in adenoid cystic carcinoma. 42
31914060 2020
2
Identification of new genes of pleomorphic adenoma. 42
31861025 2019
3
Chimeric Vastus Lateralis and Anterolateral Thigh Flap for Restoring Facial Defects and Dynamic Function following Radical Parotidectomy. 42
31688764 2019
4
CD151 regulates HGF-stimulated morphogenesis of human breast cancer cells. 61 54
19159612 2009
5
Role of Akt isoforms in HGF-induced invasive growth of human salivary gland cancer cells. 54 61
18355439 2008
6
Expression and cellular localization of TSC-22 in normal salivary glands and salivary gland tumors: implications for tumor cell differentiation. 54 61
18288391 2008
7
Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells. 54 61
16469527 2006
8
CD151 forms a functional complex with c-Met in human salivary gland cancer cells. 54 61
16139245 2005
9
TSC-22 (TGF-beta stimulated clone-22): a novel molecular target for differentiation-inducing therapy in salivary gland cancer. 54 61
15379637 2004
10
Thiazolidinediones inhibit cell growth of human oral squamous cell carcinoma in vitro independent of peroxisome proliferator-activated receptor gamma. 61 54
13679209 2003
11
Cytoplasmic TSC-22 (transforming growth factor-beta-stimulated clone-22) markedly enhances the radiation sensitivity of salivary gland cancer cells. 61 54
11944908 2002
12
Expression of peroxisome proliferator-activated receptor gamma and the growth inhibitory effect of its synthetic ligands in human salivary gland cancer cell lines. 61 54
11836575 2002
13
Leucine zipper structure of TSC-22 (TGF-beta stimulated clone-22) markedly inhibits the anchorage-independent growth of salivary gland cancer cells. 61 54
11836610 2002
14
In vivo enhancement of chemosensitivity of human salivary gland cancer cells by overexpression of TGF-beta stimulated clone-22. 61 54
10854535 2000
15
Over-expression of TSC-22 (TGF-beta stimulated clone-22) markedly enhances 5-fluorouracil-induced apoptosis in a human salivary gland cancer cell line. 54 61
10879745 2000
16
Down-regulation of TSC-22 (transforming growth factor beta-stimulated clone 22) markedly enhances the growth of a human salivary gland cancer cell line in vitro and in vivo. 54 61
9458104 1998
17
Induction of TSC-22 by treatment with a new anti-cancer drug, vesnarinone, in a human salivary gland cancer cell. 61 54
9459148 1998
18
Advanced salivary gland carcinoma expressing androgen receptor and HER2: targeted therapies first? 61
32275947 2020
19
Salivary Gland Cancer in the Era of Routine Next-Generation Sequencing. 61
32124419 2020
20
Pure abscopal effect of radiotherapy in a salivary gland carcinoma: Case report, literature review, and a search for new approaches. 61
32192840 2020
21
Tipifarnib in recurrent, metastatic HRAS-mutant salivary gland cancer. 61
32557577 2020
22
Development of sentinel lymph node biopsy technique in patients with salivary gland cancer using the IDEAL framework. 61
32576478 2020
23
C6-ceramide induces salivary adenoid cystic carcinoma cell apoptosis via IP3R-activated UPR and UPR-independent pathways. 61
32178876 2020
24
Bilateral, buccinator myomucosal advancement flaps to reconstruct central upper labial myomucosal defects after ablation of early-stage cancer in minor salivary glands. 61
32463957 2020
25
Functional characterization of a germline ETV6 variant associated with inherited thrombocytopenia, acute lymphoblastic leukemia, and salivary gland carcinoma in childhood. 61
32367453 2020
26
Targeting HER2 with Trastuzumab Deruxtecan: A Dose-Expansion, Phase I Study in Multiple Advanced Solid Tumors. 61
32213540 2020
27
Elective neck dissection in patients with salivary gland carcinoma: A systematic review and meta-analysis. 61
32430929 2020
28
Curcumin Enhances the Antitumoral Effect Induced by the Recombinant Vaccinia Neu Vaccine (rV-neuT) in Mice with Transplanted Salivary Gland Carcinoma Cells. 61
32423101 2020
29
Distant metastasis of salivary gland cancer: Incidence, management, and outcomes. 61
32097509 2020
30
Salivary duct carcinoma: Updates in histology, cytology, molecular biology, and treatment. 61
32421944 2020
31
Next-generation sequencing in salivary gland carcinoma: Targetable alterations lead to a therapeutic advantage-Multicenter experience. 61
31762146 2020
32
Nanoassembled Peptide Biosensors for Rapid Detection of Matrilysin Cancer Biomarker. 61
32196143 2020
33
Ambient ultraviolet radiation and major salivary gland cancer in the United States. 61
32246964 2020
34
The Benefits of Adjuvant Trastuzumab for HER-2-Positive Salivary Gland Cancers. 61
32310325 2020
35
Positive lymph node number and extranodal extension for predicting recurrence and survival in patients with salivary gland cancer. 61
32115841 2020
36
Targeted therapy for advanced salivary gland carcinoma based on molecular profiling: results from MyPathway, a phase IIa multiple basket study. 61
32067683 2020
37
Salivary ghost cell carcinoma: case report and proposal of a new entity. 61
31616980 2020
38
Development and validation of a clinical prediction-score model for distant metastases in major salivary gland carcinoma. 61
31959347 2020
39
Clinical outcome and comparison between squamous and non-squamous cell carcinoma of the larynx. 61
31852360 2020
40
A retrospective multicenter study of sublingual gland carcinoma in Japan. 61
31104870 2020
41
Nivolumab in patients with rare head and neck carcinomas: A single center's experience. 61
31300270 2020
42
A Phase II Trial of Pembrolizumab and Vorinostat in Recurrent Metastatic Head and Neck Squamous Cell Carcinomas and Salivary Gland Cancer. 61
31796519 2020
43
Minimal acute toxicity from proton beam therapy for major salivary gland cancer. 61
31805791 2020
44
Optimal Treatment for the High-Risk Salivary Gland Cancer. 61
32036639 2020
45
Pan-Trk immunohistochemistry reliably identifies ETV6-NTRK3 fusion in secretory carcinoma of the salivary gland. 61
31423558 2020
46
The Role of Prognostic Factors in Salivary Gland Tumors Treated by Surgery and Adjuvant Radio- or Chemoradiotherapy - A Single Institution Experience. 61
32104086 2020
47
The molecular landscape and microenvironment of salivary duct carcinoma reveal new therapeutic opportunities. 61
32292502 2020
48
68Ga-PSMA-HBED-CC PET/CT imaging for adenoid cystic carcinoma and salivary duct carcinoma: a phase 2 imaging study. 61
32089741 2020
49
Prognostic value of lymph node density for major salivary gland carcinoma without clinical lymph node metastasis. 61
31727336 2020
50
HPV-Related Multiphenotypic Sinonasal Carcinoma: A Unique Case. 61
31405309 2019
Sources

Variations for Salivary Gland Carcinoma

About this section

Cosmic variations for Salivary Gland Carcinoma:

9 (show top 50) (show all 451)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM135127924 TGFBR1 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.324A>C p.K108N 9:99129081-99129081 28
2 COSM105721467 salivary gland,mouth floor,carcinoma,mucoepidermoid carcinoma c.35G>T p.G12V 11:534288-534288 28
3 COSM97921670 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.324A>C p.K108N 9:99129081-99129081 28
4 COSM133255277 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.117A>C p.K39N 9:99129081-99129081 28
5 COSM97906020 salivary gland,minor,carcinoma,mucoepidermoid carcinoma c.324A>C p.K108N 9:99129081-99129081 28
6 COSM143041461 WASF2 salivary gland,mouth floor,carcinoma,NS c.15G>T p.T5= 1:27428876-27428876 21
7 COSM84855029 TRPV5 salivary gland,mouth floor,carcinoma,NS c.554A>G p.H185R 7:142929054-142929054 21
8 COSM99625361 TP53BP1 salivary gland,mouth floor,carcinoma,NS c.3869C>G p.T1290S 15:43422086-43422086 21
9 COSM88223810 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.501G>C p.Q167H 17:7675111-7675111 21
10 COSM87905712 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 21
11 COSM88218639 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.569C>A p.P190H 17:7674962-7674962 21
12 COSM87961733 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.661G>A p.E221K 17:7674870-7674870 21
13 COSM88043721 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.550G>C p.D184H 17:7675062-7675062 21
14 COSM87933369 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.494A>T p.Q165L 17:7675118-7675118 21
15 COSM88075150 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.483C>T p.A161= 17:7675129-7675129 21
16 COSM87897745 TP53 salivary gland,minor,carcinoma,NS c.524G>A p.R175H 17:7675088-7675088 21
17 COSM87912247 TP53 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.523C>T p.R175C 17:7675089-7675089 21
18 COSM87901886 TP53 salivary gland,minor,carcinoma,NS c.994-1G>A p.? 17:7670716-7670716 21
19 COSM88420642 THRA salivary gland,mouth floor,carcinoma,NS c.1162C>T p.R388W 17:40093071-40093071 21
20 COSM96852092 TENT5C salivary gland,minor,carcinoma,NS c.833T>A p.F278Y 1:117623701-117623701 21
21 COSM89651491 SMARCA4 salivary gland,minor,carcinoma,NS c.2372C>T p.A791V 19:11013046-11013046 21
22 COSM91381776 SMAD4 salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.993G>A p.M331I 18:51065460-51065460 21
23 COSM87293136 SLC26A2 salivary gland,mouth floor,carcinoma,NS c.1474C>T p.R492W 5:149981067-149981067 21
24 COSM89628192 SF3B1 salivary gland,minor,carcinoma,NS c.3254C>T p.A1085V 2:197397997-197397997 21
25 COSM103044749 SETD2 salivary gland,minor,carcinoma,NS c.6379C>T p.Q2127* 3:47057405-47057405 21
26 COSM84139086 SDHA salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.724G>A p.G242R 5:228287-228287 21
27 COSM87217226 RUNX1 salivary gland,minor,carcinoma,NS c.958C>T p.R320* 21:34799310-34799310 21
28 COSM88241411 RPTOR salivary gland,minor,carcinoma,NS c.734C>T p.A245V 17:80754089-80754089 21
29 COSM85226318 RNF38 salivary gland,mouth floor,carcinoma,NS c.623A>G p.H208R 9:36357890-36357890 21
30 COSM97325050 RIT1 salivary gland,mouth floor,carcinoma,NS c.286C>G p.Q96E 1:155904733-155904733 21
31 COSM86829907 RARA salivary gland,minor,carcinoma,NS c.691C>G p.L231V 17:40352391-40352391 21
32 COSM146439398 PTPN11 salivary gland,minor,carcinoma,NS c.1517C>T p.S506L 12:112489081-112489081 21
33 COSM96879738 PTEN salivary gland,NS,carcinoma,mucoepidermoid carcinoma c.760A>G p.K254E 10:87957978-87957978 21
34 COSM91776528 PPP2R1A salivary gland,mouth floor,carcinoma,NS c.548G>A p.R183Q 19:52212730-52212730 21
35 COSM96441053 PIK3CG salivary gland,minor,carcinoma,NS c.2951C>A p.P984Q 7:106886213-106886213 21
36 COSM87132308 PIK3CA salivary gland,minor,carcinoma,NS c.1633G>A p.E545K 3:179218303-179218303 21
37 COSM87138027 PIK3CA salivary gland,minor,carcinoma,NS c.3012G>A p.M1004I 3:179234169-179234169 21
38 COSM87132826 PIK3CA salivary gland,minor,carcinoma,NS c.1258T>C p.C420R 3:179210192-179210192 21
39 COSM87132245 PIK3CA salivary gland,mouth floor,carcinoma,NS c.3140A>G p.H1047R 3:179234297-179234297 21
40 COSM101277011 PBRM1 salivary gland,minor,carcinoma,NS c.2284G>C p.D762H 3:52609596-52609596 21
41 COSM84166347 NR1D1 salivary gland,mouth floor,carcinoma,NS c.*12G>A p.? 17:40093071-40093071 21
42 COSM87686111 NOTCH1 salivary gland,minor,carcinoma,NS c.403+1G>C p.? 9:136523716-136523716 21
43 COSM87645161 NOTCH1 salivary gland,minor,carcinoma,NS c.7400C>A p.S2467* 9:136496339-136496339 21
44 COSM87655472 NOTCH1 salivary gland,minor,carcinoma,NS c.1367G>A p.C456Y 9:136517826-136517826 21
45 COSM87673614 NOTCH1 salivary gland,minor,carcinoma,NS c.973A>G p.N325D 9:136518717-136518717 21
46 COSM87642161 NOTCH1 salivary gland,minor,carcinoma,NS c.5101G>C p.A1701P 9:136503248-136503248 21
47 COSM93664740 NF1 salivary gland,minor,carcinoma,NS c.3449C>G p.S1150* 17:31232834-31232834 21
48 COSM85374504 MELK salivary gland,mouth floor,carcinoma,NS c.817T>C p.W273R 9:36633183-36633183 21
49 COSM95014362 MAX salivary gland,minor,carcinoma,NS c.295+1G>A p.? 14:65077912-65077912 21
50 COSM106071509 MAP2K4 salivary gland,minor,carcinoma,NS c.584C>G p.S195W 17:12107827-12107827 21
Sources

Expression for Salivary Gland Carcinoma

About this section
Search GEO for disease gene expression data for Salivary Gland Carcinoma.
Sources

Pathways for Salivary Gland Carcinoma

About this section

Pathways related to Salivary Gland Carcinoma according to KEGG:

36
# Name Kegg Source Accession
1 Notch signaling pathway hsa04330

Pathways related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

(show all 23)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 63
Show member pathways
 13.72 SOX2 MET MDM2 KIT HGF EGFR
2
GAB1 signalosome 65
Show member pathways
 13.01 NR4A1 MET MDM2 KIT HGF EGFR
3
MAPK signaling pathway 36 1
12.62 NR4A1 MET KIT HGF EGFR
4
Pathways in cancer 36
12.57 MET MDM2 KIT HGF EGFR CDKN2A
5
Gastric cancer 36
Show member pathways
 12.4 MET KIT HGF EGFR CDKN2A BRCA1
6
MicroRNAs in cancer 36
12.37 MET MDM2 EGFR CDKN2A BRCA1
7
Downstream signaling events of B Cell Receptor (BCR) 65
Show member pathways
 12.27 NR4A1 MET MDM2 KIT HGF EGFR
8
Proteoglycans in cancer 36
12.15 MET MDM2 HGF EGFR
9
PI3K-Akt signaling pathway 36
Show member pathways
 12.06 NR4A1 MET MDM2 MAML2 KIT HGF
10
Glioma 36
Show member pathways
 12.03 MET MDM2 HGF EGFR CDKN2A BRCA1
11
Embryonic and Induced Pluripotent Stem Cells and Lineage-specific Markers 64
11.88 SOX2 MET ISL1 HGF
12
Direct p53 effectors 1
11.85 MET MDM2 HGF EGFR
13
Listeria monocytogenes entry into host cells 65
Show member pathways
 11.75 MET HGF EGFR
14
Androgen receptor signaling pathway 1
11.74 MDM2 EGFR BRCA1
15
Platinum drug resistance 36
11.62 MDM2 CDKN2A BRCA1
16
Bladder cancer 36 1
11.62 MDM2 EGFR CDKN2A
17
Adherens junction 36
11.59 MET EGFR ACTN4
18
Central carbon metabolism in cancer 36
11.57 MET KIT EGFR
19
Cardiac Progenitor Differentiation 1
11.42 SOX2 KIT ISL1
20
Signaling events mediated by TCPTP 1
Show member pathways
 11.31 MET HGF EGFR
21
Stabilization and expansion of the E-cadherin adherens junction 1
11.27 MET HGF EGFR
22
Arf6 signaling events 1
11.11 MET HGF EGFR
23
Extracellular vesicle-mediated signaling in recipient cells 1
10.97 MET HGF EGFR
Sources

GO Terms for Salivary Gland Carcinoma

About this section

Cellular components related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 nucleus GO:0005634 9.5 TSC22D1 SPHK1 SOX2 SERPINA3 NR4A1 MDM2
2 platelet alpha granule lumen GO:0031093 9.13 SERPINA3 HGF ACTN4

Biological processes related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

(show all 18)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of cell proliferation GO:0008284 9.96 SPHK1 MDM2 KIT ISL1 EGFR
2 MAPK cascade GO:0000165 9.85 MET KIT HGF EGFR
3 liver development GO:0001889 9.71 MET HGF EGFR
4 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.65 NR4A1 MDM2 HGF
5 positive regulation of protein kinase B signaling GO:0051897 9.62 MET KIT HGF EGFR
6 positive regulation of kinase activity GO:0033674 9.61 MET KIT EGFR
7 epithelial cell proliferation GO:0050673 9.58 KIT HGF
8 cellular response to growth factor stimulus GO:0071363 9.58 SPHK1 MDM2 EGFR
9 negative regulation of intracellular estrogen receptor signaling pathway GO:0033147 9.57 ISL1 BRCA1
10 positive regulation of angiogenesis GO:0045766 9.56 SPHK1 ISL1 HGF BRCA1
11 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.54 SPHK1 EGFR ACTN4
12 amyloid fibril formation GO:1990000 9.52 MDM2 CDKN2A
13 hepatocyte growth factor receptor signaling pathway GO:0048012 9.51 MET HGF
14 tongue development GO:0043586 9.49 KIT EGFR
15 somatic stem cell division GO:0048103 9.46 KIT CDKN2A
16 positive regulation of cell migration GO:0030335 9.35 SPHK1 KIT HGF EGFR ACTN4
17 positive regulation of transcription by RNA polymerase II GO:0045944 9.32 SOX2 NR4A1 MET MAML2 ISL1 HGF
18 negative regulation of hydrogen peroxide-mediated programmed cell death GO:1901299 9.16 MET HGF

Molecular functions related to Salivary Gland Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 5S rRNA binding GO:0008097 8.96 TST MDM2
2 transmembrane receptor protein tyrosine kinase activity GO:0004714 8.8 MET KIT EGFR
Sources

Sources for Salivary Gland Carcinoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....